Sonnet BioTherapeutic (SONN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
GlobeNewswireFeb 26 09:00 ET
Express News | Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates
ReutersFeb 19 08:35 ET
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
GlobeNewswireFeb 18 09:15 ET
Sonnet BioTherapeutic | 10-Q: Q1 2025 Earnings Report
SECFeb 13 16:22 ET · Announcements
Sonnet BioTherapeutics Reports Wider Q1 Net Loss, CFO Transition
Seeking AlphaFeb 13 08:42 ET
Express News | Sonnet Biotherapeutics Appoints Stephen Mcandrew, Ph.d. as Chief Business Officer
ReutersFeb 13 08:30 ET

Comments

Jaguar8

4 hours ago

NEWS

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Wednesday, 26th February at 9:00 am
Poster presented at the 2025 AACR:IO Conference
Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced targeting to the tumor microenvironment...

1

Trytosaveabit

Feb 19 07:39

news

$Sonnet BioTherapeutic (SONN.US)$ Reuters· 3 mins ago
Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates

Jaguar8

Jan 28 08:05

NEWS

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
Tuesday, 28th January at 9:05 am
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
In addition to the U.S. and EU, Sonnet's global IP coverage
now extends to China, Japan, Russia and New Zealand
Management releases "What This Mea...

Stock_Drift

Jan 24 10:51

Low Floats. 11:50am

$Millennium Group International (MGIH.US)$ $Coeptis Therapeutics (COEP.US)$ $Sonnet BioTherapeutic (SONN.US)$ $Edesa Biotech (EDSA.US)$ $U-BX Technology (UBXG.US)$ $J-Long Group (JL.US)$ $AXIL Brands (AXIL.US)$ $PainReform (PRFX.US)$ $FST Corp (KBSX.US)$ $XTI Aerospace (XTIA.US)$ $Firefly Neuroscience (AIFF.US)$ $SMX (Security Matters) (SMX.US)$ $Color Star Technology (ADD.US)$ $Transcode Therapeutics (RNAZ.US)$ $PMGC Holdings (ELAB.US)$

8

Trytosaveabit

Jan 22 15:00

news

$Sonnet BioTherapeutic (SONN.US)$ Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)".
Benzinga· just

SONN Sonnet BioTherapeutic

Trade Overview

Capital Trend

News

Comments

Trending Stocks